Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7248448 | 0.72 | PPARG (0.56) | PPARGPPARA | |
| SCHEMBL5691818 | 0.70 | PPARG (0.61) | PPARGPPARAMEN1KMT2AKDM4E | |
| SCHEMBL11596999 | 0.67 | SMN1; SMN2 (0.57) | PPARGPPARAMEN1KMT2AKDM4E | |
| SCHEMBL6602078 | 0.67 | FFAR1 (0.56) | PPARGPPARAMEN1KMT2AALDH1A1 | |
| SCHEMBL11394121 | 0.67 | PPARA (0.58) | PPARGPPARAMEN1KMT2AKDM4E | |
| SCHEMBL11598113 | 0.66 | PPARA (0.55) | PPARGPPARAMEN1KMT2AKDM4E | |
| SCHEMBL11602402 | 0.65 | PPARG (0.57) | PPARGPPARANPC1RAB9A | |
| SCHEMBL11595598 | 0.65 | PPARA (0.55) | PPARGPPARAMEN1KMT2AKDM4E | |
| SCHEMBL11599887 | 0.65 | PPARA (0.68) | PPARGPPARAMEN1KMT2AKDM4E | |
| SCHEMBL27638956 | 0.65 | PPARG (0.59) | PPARGPPARAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6664411-B2 | Beta-aryl/alpha-oxysubstituted alkylcarboxylic acids of 4-oxo-or thiocarbonylchromenes or thiochromenes; antiobesity, -cholesterol - diabetic agents; agonists of peroxisome proliferator activated receptors; kidney disorders | DR. REDDY'S LABORATORIES LIMITED (IN) | 2003-12-16 | — | — | US | disclosed |
| US-20010027198-A1 | Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR INC. | 2001-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027198-A1 | Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | CYP11B1, CYP46A1, CYP51A1 | PPARG 102/4885PPARA 144/4885TNKS2 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.